

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/425, 31/41 // 31/51, 31/44, 31/535, 31/54	A1	(11) International Publication Number: WO 97/18811 (43) International Publication Date: 29 May 1997 (29.05.97)
(21) International Application Number: PCT/US96/17633 (22) International Filing Date: 4 November 1996 (04.11.96) (30) Priority Data: 60/007.373 17 November 1995 (17.11.95) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): LOCKWOOD, Dean [US/US]; 3431 Wagner Woods Court, Ann Arbor, MI 48103 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: A METHOD OF TREATING MYOTONIC DYSTROPHY (57) Abstract <p>This invention provides a method of treating myotonic dystrophy by administering to a patient a therapeutically effective amount of a thiazolidinedione derivative or a 3H-1,2,3,5-oxathiadiazole-2 oxide derivative.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

A METHOD OF TREATING MYOTONIC DYSTROPHY

FIELD OF THE INVENTION

5

The present invention provides a method of treating myotonic dystrophy.

10

BACKGROUND OF THE INVENTION

Myotonic dystrophy is the most common form of muscular dystrophy. This disease affects about one person in 8,000 and is a multisystem autosomal-dominant disease, carried on Chromosome 19; that has a wide spectrum of symptoms. In general, the major symptoms of myotonic dystrophy arise from damage to skeletal, cardiac, and smooth muscles. Specific symptoms include, but are not limited to, cataracts, muscle weakness (particularly in the face, forearms, and foot dorsiflexors), myotonia, muscle wasting, respiratory distress, hypotonia, feeding difficulty, talipes, mental retardation, cardiac arrhythmias (such as heart block, conduction disturbance, and atrial tachyarrhythmias) and respiratory disturbances (such as respiratory failure, sleep apnea, and hypersomnia).

The genetic defect that underlies myotonic dystrophy has recently been shown to involve the expansion of CTG repeats in the 3'-untranslated region of a gene that codes for a serine kinase. This gene is located at q13.3 on the long arm of Chromosome 19.

It has also been noticed that persons having myotonic dystrophy exhibit insulin resistance. See, for example, Livingston, et al., "Myotonic Dystrophy: Phenotype-Genotype and Insulin Resistance," Diabetes

35

- 2 -

Review, 1994;2(1):29-42, which is hereby incorporated by reference.


Thus, it would be useful to have compounds which can be used to treat myotonic dystrophy.

5

SUMMARY OF THE INVENTION

The present invention provides a method of
 10 treating myotonic dystrophy comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula I

15



20

wherein R^1 and R^2 are the same or different and each represents a hydrogen atom or a C_1 - C_5 alkyl group;

25

R^3 represents a hydrogen atom, a C_1 - C_6 aliphatic acyl group, an alicyclic acyl group, an aromatic acyl group, a heterocyclic acyl group, an araliphatic acyl group, a (C_1 - C_6 alkoxy)carbonyl group, or an aralkyl-oxycarbonyl group;

30

R^4 and R^5 are the same or different and each represents a hydrogen atom, a C_1 - C_5 alkyl group or a C_1 - C_5 alkoxy group, or R^4 and R^5 together represent a C_1 - C_4 alkylenedioxy group;

n is 1, 2, or 3;

W represents the $-CH_2-$, CO , or $CH-OR^6$ group (in which R^6 represents any 1 of the atoms or groups defined for R^3 and may be the same as or different from R^3); and


35

-3-

Y and Z are the same or different and each represents an oxygen atom or an imino (=NH) group; and pharmaceutically acceptable salts thereof.

In a preferred embodiment of the method, the compound of Formula I is 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]-phenyl]methyl]-2,4-thiazolidinedione.

Another embodiment provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula II



wherein R_{11} is substituted or unsubstituted alkyl, alkoxy, cycloalkyl, phenylalkyl, phenyl, aromatic acyl group, a 5- or 6-membered heterocyclic group including 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, or a group of the formula




wherein R_{13} and R_{14} are the same or different and each is lower alkyl or R_{13} and R_{14} are combined to each other either directly or as interrupted by a heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur to form a 5- or 6-membered ring; wherein R_{12} means a bond or a lower alkylene group; and wherein L_1 and L_2 are the same or different and each is hydrogen or lower alkyl or L_1 and L_2 are combined to

- 4 -


form an alkylene group, or a pharmaceutically acceptable salt thereof.

Also provided is a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula III



wherein R_{15} and R_{16} are independently hydrogen, lower alkyl containing 1 to 6 carbon atoms, alkoxy containing 1 to 6 carbon atoms, halogen, ethynyl, nitrile, methylthio, trifluoromethyl, vinyl, nitro, or halogen substituted benzyloxy; n is 0 to 4 and the pharmaceutically acceptable salts thereof.

The present invention also provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula IV



wherein the dotted line represents a bond or no bond;

V is $-\text{CH}=\text{CH}-$, $-\text{N}=\text{CH}-$, $-\text{CH}=\text{N}-$ or S;

D is CH_2 , CHOH , CO , $\text{C}=\text{NOR}_{17}$ or $\text{CH}=\text{CH}$;

X is S, O, NR_{18} , $-\text{CH}=\text{N}$ or $-\text{N}=\text{CH}$;

Y is CH or N;

Z is hydrogen, (C_1-C_7) alkyl, (C_3-C_7) cycloalkyl, phenyl, naphthyl, pyridyl, furyl, thienyl, or phenyl

-5-


mono- or disubstituted with the same or different groups which are (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, fluoro, chloro, or bromo;

Z₁ is hydrogen or (C₁-C₃)alkyl;

5 R₁₇ and R₁₈ are each independently hydrogen or methyl; and n is 1, 2, or 3; the pharmaceutically acceptable cationic salts thereof; and the pharmaceutically acceptable acid addition salts thereof when the compound contains a basic nitrogen.

10 In another embodiment, the present invention provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula V

15



V

20 wherein the dotted line represents a bond or no bond; A and B are each independently CH or N, with the proviso that when A or B is N, the other is CH; X₁ is S, SO, SO₂, CH₂, CHOH, or CO; n is 0 or 1;

25 Y₁ is CHR₂₀ or R₂₁, with the proviso that when n is 1 and Y₁ is NR₂₁, X₁ is SO₂ or CO;

Z₂ is CHR₂₂, CH₂CH₂, CH=CH, CH—CH, OCH₂, SCH₂,



SOCH₂, or SO₂CH₂;


30 R₁₉, R₂₀, R₂₁, and R₂₂ are each independently hydrogen or methyl; and

X₂ and X₃ are each independently hydrogen, methyl, trifluoromethyl, phenyl, benzyl, hydroxy, methoxy, phenoxy, benzyloxy, bromo, chloro, or fluoro;

-6-


a pharmaceutically acceptable cationic salt thereof; or a pharmaceutically acceptable acid addition salt thereof when A or B is N.

In another embodiment, the present invention provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula VI



or a pharmaceutically acceptable salt thereof, wherein R_{23} is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl, or mono- or disubstituted phenyl wherein said substituents are independently alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 3 carbon atoms, halogen, or trifluoromethyl.

In another embodiment, the present invention provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula VII



or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

A_2 represents an alkyl group, a substituted or unsubstituted aryl group, or an aralkyl group wherein the alkylene or the aryl moiety may be substituted or unsubstituted;

-7-

A₃ represents a benzene ring having in total up to 3 optional substituents;

R₂₄ represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the alkyl, or the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; or


A₂ together with R₂₄ represents substituted or unsubstituted C₂₋₃ polymethylene group, optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group;

R₂₅ and R₂₆ each represent hydrogen, or R₂₅ and R₂₆ together represent a bond;

X₄ represents O or S; and

n represents an integer in the range of from 2 to 6.

In another embodiment, the present invention provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula VIII



or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate therefor, wherein:

R₂₇ and R₂₈ each independently represent an alkyl group, a substituted or unsubstituted aryl group, or an aralkyl group being substituted or unsubstituted in the aryl or alkyl moiety; or

R₂₇ together with R₂₈ represents a linking group, the linking group consisting of an optionally substituted

-8-

methylene group and either a further optionally substituted methylene group or an O or S atom, optional substituents for the said methylene groups being selected from alkyl-, aryl, or aralkyl, or substituents of adjacent methylene groups together with the carbon atoms to which they are attached form a substituted or unsubstituted phenylene group;


R₂₉ and R₃₀ each represent hydrogen, or R₂₉ and R₃₀ together represent a bond;

A₄ represents a benzene ring having in total up to 3 optional substituents;

X₅ represents O or S; and

n represents an integer in the range of from 2 to 6.

In another embodiment, the present invention provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula IX



or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

A₅ represents a substituted or unsubstituted aromatic heterocyclyl group;

A₆ represents a benzene ring having in total up to 5 substituents;


X₆ represents O, S, or NR₃₂ wherein R₃₂ represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

Y₂ represents O or S;

-9-

R_{31} represents an alkyl, aralkyl, or aryl group; and n represents an integer in the range of from 2 to 6.

In another embodiment, the present invention provides a method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula X



or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

15 A_7 represents a substituted or unsubstituted aryl group;

A_8 represents a benzene ring having in total up to 5 substituents;

20 X_8 represents O, S, or NR_{39} wherein R_{39} represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

25 Y_3 represents O or S;

R_{37} represents hydrogen;

R_{38} represents hydrogen or an alkyl, aralkyl, or aryl group or R_{37} together with R_{38} represents a bond; and n represents an integer in the range of from 2 to 6.

30




DETAILED DESCRIPTION OF THE INVENTION

Compounds used in the method of the present invention, which are 5-[4-(chromoanalkoxy)benzyl]

35

-10-

thiazolidene derivatives, may be represented by the Formulas (Ia), (Ib), and (Ic)



(in which R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , n , Y , and Z are as defined above) and include pharmaceutically acceptable salts thereof.

25 In the compounds of the invention, where R^1 or R^2 represents an alkyl group, the alkyl group may be a straight or branched chain alkyl group having from 1 to 5 carbon atoms and is preferably a primary or secondary alkyl group, for example the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, or isopentyl group.

30 Where R^3 or R^6 represents an aliphatic acyl group, the aliphatic acyl group preferably has from 1 to 6 carbon atoms and can include one or more carbon-carbon double or triple bonds. Examples of such groups include the formyl, acetyl, propionyl, butyryl,

35

-11-

isobutyryl, pivaloyl, hexanoyl, acryloyl, methacryloyl, and crotonyl groups.

Where R^3 or R^6 represents an alicyclic acyl group, it is preferably a cyclopentanecarbonyl, cyclohexane-carbonyl, or cycloheptanecarbonyl group.

Where R^3 or R^6 represents an aromatic acyl group, the aromatic moiety thereof may optionally have one or more substituents (for example, nitro, amino, alkylamino, dialkylamino, alkoxy, halo, alkyl, or hydroxy substituents); examples of such aromatic acyl groups included the benzoyl, p-nitrobenzoyl, m-fluorobenzoyl, o-chlorobenzoyl, p-aminobenzoyl, m-(dimethylamino)benzoyl, o-methoxybenzoyl, 3,4-dichlorobenzoyl, 3,5-di-t-butyl-4-hydroxybenzoyl, and 1-naphthoyl groups.

Where R^3 or R^6 represents a heterocyclic acyl group, the heterocyclic moiety thereof preferably has one or more, preferably one, oxygen, sulfur, or nitrogen heteroatoms and has from 4 to 7 ring atoms; examples of such heterocyclic acyl groups include the 2-furoyl, 3-thenoyl, 3-pyridinecarbonyl (nicotinoyl), and 4-pyridinecarbonyl groups.

Where R^3 or R^6 represents an araliphatic acyl group, the aliphatic moiety thereof may optionally have one or more carbon-carbon double or triple bonds and the aryl moiety thereof may optionally have one or more substituents (for example, nitro, amino, alkylamino, dialkylamino, alkoxy, halo, alkyl, or hydroxy substituents); examples of such araliphatic acyl groups include the phenylacetyl, p-chlorophenylacetyl, phenylpropionyl, and cinnamoyl groups.

Where R^3 or R^6 represents a (C_1 - C_6 alkoxy)carbonyl group, the alkyl moiety thereof may be any one of those alkyl groups as defined for R^1 and R^2 , but is preferably a methyl or ethyl group, and the alkoxycarbonyl group represented by R^3 or R^6 is

-12-

therefore preferably a methoxycarbonyl or ethoxycarbonyl group.

Where R^3 or R^6 represents an aralkyloxycarbonyl group, the aralkyl moiety thereof may be any one of those included within the araliphatic acyl group represented by R^3 or R^6 , but is preferably a benzyloxycarbonyl group.

Where R^4 and R^5 represent alkyl groups, the alkyl groups can be the same or different and can be straight or branched chain alkyl groups. The alkyl groups preferably have from 1 to 5 carbon atoms and examples include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and isopentyl groups.

Where R^4 and R^5 represent alkoxy groups, the alkoxy groups can be the same or different and can be straight or branched chain groups, preferably having from 1 to 4 carbon atoms. Examples include the methoxy, ethoxy, propoxy, isopropoxy, and butoxy groups. Alternatively, R^4 and R^5 can together represent a C_1 - C_4 alkylenedioxy group, more preferably a methylenedioxy or ethylenedioxy group.

Preferred classes of compounds of Formula I are as follows:

(1) Compounds in which R^3 represents a hydrogen atom, a C_1 - C_6 aliphatic acyl group, an aromatic acyl group, or a heterocyclic acyl group.

(2) Compounds in which Y represents an oxygen atom; R^1 and R^2 are the same or different and each represents a hydrogen atom or a C_1 - C_5 alkyl group; R^3 represents a hydrogen atom, a C_1 - C_6 aliphatic acyl group, an aromatic acyl group, or a pyridinecarbonyl group; and R^4 and R^5 are the same or different and each represents a hydrogen atom, a C_1 - C_5 alkyl group, or a C_1 or C_2 alkoxy group.

(3) Compounds as defined in (2) above, in which: R^1 , R^2 , R^4 , and R^5 are the same or different and each

-13-

represents a hydrogen atom or a C₁-C₅ alkyl group; n is 1 or 2; and W represents the -CH₂- or >CO group.

5 (4) Compounds as defined in (3) above, in which R³ represents a hydrogen atom, a C₁-C₅ aliphatic acyl group, a benzoyl group, or a nicotinyl group.

(5) Compounds as defined in (4) above, in which: R¹ and R⁴ are the same or different and each represents a C₁-C₅ alkyl group; R² and R⁵ are the same or different and each represents the hydrogen atom or the methyl group; and R³ represents a hydrogen atom or a
10 C₁-C₄ aliphatic acyl group.

(6) Compounds in which: W represents the -CH₂- or >CO group; Y and Z both represent oxygen atoms; n is 1 or 2; R¹ and R⁴ are the same or different and each
15 represents a C₁-C₄ alkyl group; R² and R⁵ are the same or different and each represents the hydrogen atom or the methyl group; and R³ represents a hydrogen atom or a C₁-C₄ aliphatic acyl group.

(7) Compounds as defined in (6) above, in which
20 n is 1.

(8) Compounds as defined in (6) or (7) above, in which W represents the -CH₂- group.

Preferred compounds among the compounds of Formula I are those wherein:

25 R¹ is a C₁-C₄ alkyl group, more preferably a methyl or isobutyl group, most preferably a methyl group;

R² is a hydrogen atom or a C₁-C₄ alkyl group, preferably a hydrogen atom, or a methyl or isopropyl
30 group, more preferably a hydrogen atom or a methyl group, most preferably a methyl group;

R³ is a hydrogen atom, a C₁-C₄ aliphatic acyl group, an aromatic acyl group or a pyridinecarbonyl group, preferably a hydrogen atom, or an acetyl,
35 butyryl, benzoyl, or nicotinyl group, more preferably a

-14-

hydrogen atom or an acetyl, butyryl or benzoyl group, most preferably a hydrogen atom or an acetyl group;

5 R^4 is a hydrogen atom, a C_1 - C_4 alkyl group or a C_1 or C_2 alkoxy group, preferably a methyl, isopropyl, t-butyl, or methoxy group, more preferably a methyl or t-butyl group, most preferably a methyl group;

10 R^5 is a hydrogen atom, a C_1 - C_4 alkyl group or a C_1 or C_2 alkoxy group, preferably a hydrogen atom, or a methyl or methoxy group, more preferably a hydrogen atom or a methyl group, and most preferably a methyl group;

n is 1 or 2, preferably 1;


Y is an oxygen atom;

15 Z is an oxygen atom or an imino group, most preferably an oxygen atom; and


W is a $-CH_2-$ or $>C=O$ group, preferably a $-CH_2-$ group.

Referring to the general Formula II, the substituents may be any from 1 to 3 selected from
20 nitro, amino, alkylamino, dialkylamino, alkoxy, halo, alkyl, or hydroxy, the aromatic acyl group may be benzoyl and naphthoyl. The alkyl group R_{11} may be a straight chain or branched alkyl of 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl,
25 n-butyl, i-butyl, t-butyl, n-pentyl, i-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl; the cycloalkyl group R_{11} may be a cycloalkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, and cycloheptyl; and the phenylalkyl group R_{11} may be a
30 phenylalkyl group of 7 to 11 carbon atoms such as benzyl and phenethyl. As examples of the heterocyclic group R_{11} may be mentioned 5- or 6-membered groups each including 1 or 2 hetero-atoms selected from among nitrogen, oxygen, and sulfur, such as pyridyl, thienyl,
35 furyl, thiazolyl, etc. When R_{11} is


- 15 -



the lower alkyls R_{13} and R_{14} may each be a lower alkyl of 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, and n-butyl. When R_{13} and R_{14} are combined to each other to form a 5- or 6-membered heterocyclic group as taken together with the adjacent N atom, i.e., in the form of




this heterocyclic group may further include a heteroatom selected from among nitrogen, oxygen, and sulfur as exemplified by piperidino, morpholino, pyrrolidino, and piperazino. The lower alkylene group R_{12} may contain 1 to 3 carbon atoms and thus may be, for example, methylene, ethylene, or trimethylene. The bond R_{12} is equivalent to the symbol "-", ".", or the like which is used in chemical structural formulas, and when R_{12} represents such a bond, the compound of general Formula II is represented by the following general Formula II(a)



Thus, when R_{12} is a bond, the atoms adjacent thereto on both sides are directly combined together. As examples of the lower alkyls L_1 and L_2 , there may be mentioned lower alkyl groups of 1 to 3 carbon atoms, such as methyl and ethyl. The alkylene group formed as

-16-

L_1 and L_2 are joined together is a group of the formula $-(CH_2)_n-$ [where n is an integer of 2 to 6]. The cycloalkyl, phenylalkyl, phenyl, and heterocyclic groups mentioned above, as well as said heterocyclic group



may have 1 to 3 substituents in optional positions on the respective rings. As examples of such substituents may be mentioned lower alkyls (e.g., methyl, ethyl, etc.), lower alkoxy groups (e.g., methoxy, ethoxy, etc.), halogens (e.g., chlorine, bromine, etc.), and hydroxyl. The case also falls within the scope of the general Formula II that an alkylenedioxy group of the formula $-O-(CH_2)_m-O-$ [is an integer of 1 to 3], such as methylenedioxy, is attached to the two adjacent carbon atoms on the ring to form an additional ring.

The preferred compounds of Formula III are those wherein R_{15} and R_{16} are independently hydrogen, lower alkyl containing 1 to 6 carbon atoms, alkoxy containing 1 to 6 carbon atoms, halogen, ethynyl, nitrile, trifluoromethyl, vinyl, or nitro; n is 1 or 2 and the pharmaceutically acceptable salts thereof.

Preferred in Formula IV are compounds wherein the dotted line represents no bond, particularly wherein D is CO or CHOH. More preferred are compounds wherein V is $-CH=CH-$, $-CH=N-$, or S and n is 2, particularly those compounds wherein X is O and Y is N, X is S and Y is N, X is S and Y is CH or X is $-CH=N-$ and Y is CH. In the most preferred compounds X is O or S and Y is N forming an oxazol-4-yl, oxazol-5-yl, thiazol-4-yl, or thiazol-5-yl group; most particularly a 2-[(2-thienyl), (2-furyl), phenyl, or substituted phenyl]-5-methyl-4-oxazolyl group.

-17-

The preferred compounds in Formula V are:

- a) those wherein the dotted line represents no bond, A and B are each CH, X_1 is CO, n is 0, R_{19} is hydrogen, Z_2 is CH_2CH_2 or $CH=CH$ and X_3 is hydrogen, particularly when X_2 is hydrogen, 2-methoxy, 4-benzyloxy, or 4-phenyl;
- b) those wherein A and B are each CH, X_1 is S or SO_2 , n is 0, R_{19} is hydrogen, Z_2 is CH_2CH_2 , and X_3 is hydrogen, particularly when X_2 is hydrogen or 4-chloro.

A preferred group of compounds is that of Formula VI wherein R_{23} is (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, phenyl, halophenyl, or (C_1-C_6) alkylphenyl. Especially preferred within this group are the compounds where R_{23} is phenyl, methylphenyl, fluorophenyl, chlorophenyl, or cyclohexyl.

When used herein with regard to Formulas VII through X, the term "aryl" includes phenyl and naphthyl, substituted phenyl, optionally substituted with up to 5, preferably up to 3, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxy, amino, nitro, carboxy, alkoxycarbonyl, alkoxycarbonyl alkyl, alkylcarbonyloxy, or alkylcarbonyl groups.

The term "halogen" refers to fluorine, chlorine, bromine, and iodine; preferably chlorine.

The terms "alkyl" and "alkoxy" relate to groups having straight or branched carbon chains, containing up to 12 carbon atoms.

Suitable alkyl groups are C_{1-12} alkyl groups, especially C_{1-6} alkyl groups, e.g., methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, or tert-butyl groups.

Suitable substituents for any alkyl group include those indicated above in relation to the term "aryl".

-18-

Suitable substituents for any heterocyclyl group include up to 4 substituents selected from the group consisting of alkyl, alkoxy, aryl, and halogen or any 2 substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said 2 substituents may themselves be substituted or unsubstituted.

A most preferred compound of the present invention is:

5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl)methyl]-2,4-thiazolidinedione.

Other preferred compounds of the present method include ciglitazone, pioglitazone, darglitazone, englitazone, and BRL 49653.

Ciglitazone is also known as 5-[p-[(1-Methylcyclohexyl)methoxy]benzyl]-2,4-thiazolidinedione.

Pioglitazone is also known as 5-[p-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione.

Darglitazone is also known as 5-[p-[3-(5-Methyl-2-phenyl-4-oxazolyl)propionyl]benzyl]-2,4-thiazolidinedione.

Englitazone is also known as 5-[[2-(2R)-2-Benzyl-6-chromanyl)methyl]-2,4-thiazolidinedione.

BRL 49653 is also known as 5-[(4-[2-Methyl-2-(prindinylamino)ethoxy]phenyl)methyl]-2,4-thiazolidinedione-(Z)-2-butenedioate (1:1).

The term "patient" includes humans and other animals.

The compounds of Formulas I through X are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.

-19-

Pharmaceutically acceptable acid addition salts of the compounds of Formulas I through X include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66:1-19).

The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner or as above. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to

-20-

their respective free base for purposes of the present invention.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66:1-19).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner or as above. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in different configurations. The compounds can, therefore, form stereoisomers. Although these are all represented herein by a limited number of molecular

-21-

formulas, the present invention includes the use of both the individual, isolated isomers and mixtures, including racemates, thereof. Where stereospecific synthesis techniques are employed or optically active compounds are employed as starting materials in the preparation of the compounds, individual isomers may be prepared directly; on the other hand, if a mixture of isomers is prepared, the individual isomers may be obtained by conventional resolution techniques, or the mixture may be used as it is, without resolution.

Furthermore, the thiazolidene part of the compound of Formulas I through X can exist in the form of tautomeric isomers. All of the tautomers are represented by Formulas I through X, and are intended to be a part of the present invention.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose,

-22-

sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and

-23-

emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 600 mg preferably 0.5 mg to 400 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

The compounds of the present invention, and methods of making these compounds, are known and


- 24 -

disclosed in U.S. Patents 5,223,522 issued June 29, 1993; 5,132,317 issued July 12, 1992; 5,120,754 issued June 9, 1992; 5,061,717 issued October 29, 1991; 4,897,405 issued January 30, 1990; 4,873,255 issued
5 October 10, 1989; 4,687,777 issued August 18, 1987; 4,572,912, issued February 25, 1986; and 4,287,200, issued September 1, 1981. These issued patents are incorporated herein by reference.

- 25 -

CLAIMS

1. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula I



15 wherein R^1 and R^2 are the same or different and each represents a hydrogen atom or a C_1 - C_5 alkyl group;

20 R^3 represents a hydrogen atom, a C_1 - C_6 aliphatic acyl group, an alicyclic acyl group, an aromatic acyl group, a heterocyclic acyl group, an araliphatic acyl group, a (C_1 - C_6 alkoxy)carbonyl group, or an aralkyloxycarbonyl group;

25 R^4 and R^5 are the same or different and each represents a hydrogen atom, a C_1 - C_5 alkyl group or a C_1 - C_5 alkoxy group, or R^4 and R^5 together represent a C_1 - C_4 alkylenedioxy group;

n is 1, 2, or 3;

30 W represents the $-CH_2-$, CO , or $CH-OR^6$ group (in which R^6 represents any one of the atoms or groups defined for R^3 and may be the same as or different from R^3); and

Y and Z are the same or different and each represents an oxygen atom or an imino ($=NH$) group; and pharmaceutically acceptable salts thereof.

2. A method of treating myotonic dystrophy, the method comprising administering to a patient


-26-

- 5 having myotonic dystrophy a therapeutically effective amount of a compound of Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
3. The method of Claim 2 comprising administering to the patient a therapeutically effective amount of a compound of Formula wherein Y and Z are oxygen.
 4. The method of Claim 2 comprising administering to the patient a therapeutically effective amount of a compound of Formula I wherein W is $-\text{CH}_2-$.
 5. The method of Claim 2 comprising administering to the patient a therapeutically effective amount of a compound of Formula wherein n is 1.
 6. The method of Claim 2 comprising administering to the patient a therapeutically effective amount of a compound of Formula I wherein R_1 , R_2 , R_4 , and R_5 are lower alkyl and R_3 is H.
 7. The method of Claim 2 comprising administering to the patient a therapeutically effective amount of a compound of Formula I wherein Z and Y are oxygen, n is 1, and W is $-\text{CH}_2-$.
 8. The method of Claim 2 comprising administering to the patient a therapeutically effective amount of a compound of Formula I wherein the compound is 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione.
 9. A method of treating myotonic dystrophy, the method comprising administering to a patient


- 27 -

having myotonic dystrophy a therapeutically effective amount of a compound of Formula II

5



10 wherein R₁₁ is substituted or unsubstituted alkyl,
alkoxy, cycloalkyl, phenylalkyl, phenyl, aromatic
acyl group, a 5- or 6-membered heterocyclic group
including 1 or 2 heteroatoms selected from the
group consisting of nitrogen, oxygen, and sulfur,
15 or a group of the formula



20

wherein R_{13} and R_{14} are the same or different and each is lower alkyl or R_{13} and R_{14} are combined to each other either directly or as interrupted by a heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur to form a 5- or 6-membered ring;

25

wherein R_{12} means a bond or a lower alkylene group; and

30


wherein L₁ and L₂ are the same or different and each is hydrogen or lower alkyl or L₁ and L₂ are combined to form an alkylene group, or a pharmaceutically acceptable salt thereof.

10. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound according to

-28-

- 5 Claim 9 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
11. The method of Claim 10 comprising administering to the patient a therapeutically effective amount of a compound of Formula II wherein the compound is pioglitazone.
12. The method of Claim 10 comprising administering to the patient a therapeutically effective amount of a compound of Formula II wherein the compound is ciglitazone.
13. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula III


5



- 10 wherein R_{15} and R_{16} are independently hydrogen, lower alkyl containing 1 to 6 carbon atoms, alkoxy containing 1 to 6 carbon atoms, halogen, ethynyl, nitrile, methylthio, trifluoromethyl, vinyl, nitro, or halogen substituted benzyloxy;
- 15 n is 0 to 4 and the pharmaceutically acceptable salts thereof.
14. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula IV

- 29 -

5



10

wherein the dotted line represents a bond or no bond;

V is $-\text{CH} = \text{CH}-$, $-\text{N} = \text{CH}-$, $-\text{CH} = \text{N}-$ or S;

D is CH_2 , CHOH , CO , $\text{C} = \text{NOR}_{17}$ or $\text{CH} = \text{CH}$;

X is S, O, NR_{18} , $-\text{CH} = \text{N}$ or $-\text{N} = \text{CH}$;

Y is CH or N;

15

Z is hydrogen, (C_1-C_7) alkyl,

(C_3-C_7) cycloalkyl, phenyl, naphthyl, pyridyl, furyl, thienyl, or phenyl mono- or disubstituted with the same or different groups which are (C_1-C_3) alkyl, trifluoromethyl, (C_1-C_3) alkoxy, fluoro, chloro, or bromo;

20

Z_1 is hydrogen or (C_1-C_3) alkyl;

R_{17} and R_{18} are each independently hydrogen or methyl; and n is 1, 2, or 3;


25

the pharmaceutically acceptable cationic salts thereof;

and the pharmaceutically acceptable acid addition salts thereof when the compound contains a basic nitrogen.

15. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula V

5



10

wherein the dotted line represents a bond or no bond;


-30-

A and B are each independently CH or N, with the proviso that when A or B is N, the other is CH;

X_1 is S, SO, SO₂, CH₂, CHOH, or CO;

n is 0 or 1;

Y_1 is CHR₂₀ or R₂₁, with the proviso that when n is 1 and Y_1 is NR₂₁, X_1 is SO₂ or CO;

Z_2 is CHR₂₂, CH₂CH₂, CH=CH, , OCH₂,

SCH₂, SOCH₂ or SO₂CH₂;


R₁₉, R₂₀, R₂₁, and R₂₂ are each independently hydrogen or methyl; and

X_2 and X_3 are each independently hydrogen, methyl, trifluoromethyl, phenyl, benzyl, hydroxy, methoxy, phenoxy, benzyloxy, bromo, chloro, or fluoro;

a pharmaceutically acceptable cationic salt thereof;

or a pharmaceutically acceptable acid addition salt thereof when A or B is N.

16. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula VI



VI


or a pharmaceutically acceptable salt thereof, wherein R₂₃ is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl, or mono- or disubstituted phenyl wherein said substituents are independently alkyl of 1 to

-31-

15 6 carbon atoms, alkoxy of 1 to 3 carbon atoms, halogen, or trifluoromethyl.

17. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula VII

5



10

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

15 A_2 represents an alkyl group, a substituted or unsubstituted aryl group, or an aralkyl group wherein the alkylene or the aryl moiety may be substituted or unsubstituted;

20 A_3 represents a benzene ring having in total up to 3 optional substituents;

25 R_{24} represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the alkyl, or the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

30 or A_2 together with R_{24} represents substituted or unsubstituted C_{2-3} polymethylene group, optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group;


-32-

R_{25} and R_{26} each represent hydrogen, or R_{25} and R_{26} together represent a bond;

X_4 represents O or S; and

n represents an integer in the range of from 2 to 6.

18. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula VIII



10 or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate therefor, wherein:

15 R_{27} and R_{28} each independently represent an alkyl group, a substituted or unsubstituted aryl group, or an aralkyl group being substituted or unsubstituted in the aryl or alkyl moiety;

20 or R_{27} together with R_{28} represents a linking group, the linking group consisting of an optionally substituted methylene group and either a further optionally substituted methylene group or an O or S atom, optional substituents for the said methylene groups being selected from alkyl-, aryl, or aralkyl, or substituents of adjacent methylene groups together with the carbon atoms to which they are attached form a substituted or unsubstituted phenylene group;


25 R_{29} and R_{30} each represent hydrogen, or R_{29} and R_{30} together represent a bond;

-33-

30 A_4 represents a benzene ring having in total up to 3 optional substituents;
 X_5 represents O or S; and
 n represents an integer in the range of from 2 to 6.

19. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of a compound of Formula IX

5



10 or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

15 A_5 represents a substituted or unsubstituted aromatic heterocyclyl group;

A_6 represents a benzene ring having in total up to 5 substituents;

20 X_6 represents O, S, or NR_{32} wherein R_{32} represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

Y_2 represents O or S;


25 R_{31} represents an alkyl, aralkyl, or aryl group; and

n represents an integer in the range of from 2 to 6.

20. A method of treating myotonic dystrophy, the method comprising administering to a patient

- 34 -

having myotonic dystrophy a therapeutically effective amount of a compound of Formula X



10 or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

15 A_7 represents a substituted or unsubstituted aryl group;

A_8 represents a benzene ring having in total up to 5 substituents;

20 X_8 represents O, S, or NR_{39} wherein R_{39} represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

Y_3 represents O or S;

R_{37} represents hydrogen;

25 R_{38} represents hydrogen or an alkyl, aralkyl, or aryl group or R_{37} together with R_{38} represents a bond; and

n represents an integer in the range of from 2 to 6.

21. A method of treating myotonic dystrophy, the method comprising administering to a patient having myotonic dystrophy a therapeutically effective amount of:

-35-

- 5 [(±)-5-[(4-[2-Methyl-2-(pyridinylamino)-ethoxy]phenyl)methyl]-2,4-thiazolidinedione-(Z)-2-butenedioate;
 englitazone; or
 darglitazone.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 96/17633

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/425 A61K31/41 //A61K31/51,A61K31/44,A61K31/535,
A61K31/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 572 912 A (YOSHIOKA T. ET AL.) 25 February 1986 cited in the application see the whole document ---	1-8
A	US 5 120 754 A (CLARK D.A.) 9 June 1992 cited in the application see the whole document ---	9,15
A	US 4 897 405 A (ALESSI ET AL.) 30 January 1990 cited in the application see the whole document ---	13
A	US 5 132 317 A (CANTELLO ET AL.) 21 July 1992 cited in the application see the whole document ---	20
-/-		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

30 January 1997

Date of mailing of the international search report

11.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Gac, G

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 96/17633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 287 200 A (KAWAMATSU ET AL.) 1 September 1981 cited in the application see the whole document ---	1,10,12
A	AM. J. PHYSIOL., vol. 265, no. 4Pt2, 1993, pages R726-R732, XP000616559 DUBEY ET AL.: "Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats" see the whole document ---	9,11
A	HYPERTENSION, vol. 24, no. 2, 1994, pages 170-175, XP000616557 ZHANG ET AL.: "Effects of pioglitazone on calcium channels in vascular smooth muscle" see the whole document ---	9,11
A	HYPERTENSION, vol. 26, no. 3, 19 - 22 September 1995, page 577 XP000616558 PERSHADSINGH ET AL.: "Thiazolidinediones inhibit PDGF-induced proliferation and promote differentiation of human aortic smooth muscle cells in culture" see abstract nr P156 -----	9,12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/17633

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-21
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/17633

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4572912	25-02-86	JP-C- 1604002	22-04-91
		JP-B- 2031079	11-07-90
		JP-A- 60051189	22-03-85
		AU-B- 570067	03-03-88
		AU-A- 3255984	07-03-85
		CA-A- 1263395	28-11-89
		DE-A- 3470742	01-06-88
		EP-A- 0139421	02-05-85
		IE-B- 58036	16-06-93
US-A-5120754	09-06-92	WO-A- 8908650	21-09-89
		US-A- 5223522	29-06-93
		CA-A- 1328872	26-04-94
		DE-D- 68912952	24-03-94
		DE-T- 68912952	11-05-94
		EP-A- 0332331	13-09-89
		PT-B- 89913	31-05-94
		US-A- 5061717	29-10-91
US-A-4897405	30-01-90	AU-A- 5369490	25-10-90
		CA-A- 2015032	21-10-90
		CN-A- 1046528	31-10-90
		EP-A- 0393941	24-10-90
		GB-A- 2230528	24-10-90
		JP-A- 2292272	03-12-90
US-A-5132317	21-07-92	AU-A- 6128590	28-02-91
		CA-A- 2023905	26-02-91
		DE-D- 69006984	07-04-94
		DE-T- 69006984	09-06-94
		EP-A- 0415605	06-03-91
		JP-A- 3090071	16-04-91
US-A-4287200	01-09-81	JP-C- 1433701	07-04-88
		JP-A- 55022636	18-02-80
		JP-B- 62042903	10-09-87
		CA-A- 1131644	14-09-82
		EP-A- 0008203	20-02-80
		US-A- 4340605	20-07-82
		US-A- 4438141	20-03-84

Information on patent family members

National Application No.

PCT/US 96/17633

Patent document
cited in search report

Publication
date

Patent family member(s)

Publication
date

US-A-4287200

US-A- 4444779

24-04-84